AbbVie (ABBV) EBITDA (2012 - 2026)

AbbVie (ABBV) has reported EBITDA for 15 consecutive years, with $6.4 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 31.43% year-over-year to $6.4 billion in Q2 2026; TTM through Jun 2026 was $16.9 billion, a 53.81% increase from a year earlier, with the FY2025 full-year figure at $15.1 billion, up 64.99% from the prior year.
• EBITDA was $6.4 billion for Q2 2026 at AbbVie, up from $4.0 billion in the prior quarter.
• Over five years, EBITDA peaked at $6.4 billion in Q2 2026 and troughed at -$1.5 billion in Q4 2024.
• A 5-year average of $3.6 billion and a median of $3.9 billion in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 146.64% in 2024 and surged 404.97% in 2025, its largest moves.
• Over 5 years, EBITDA stood at $5.5 billion in 2022, then slumped by 41.93% to $3.2 billion in 2023, then tumbled by 146.64% to -$1.5 billion in 2024, then surged by 404.97% to $4.5 billion in 2025, then soared by 41.55% to $6.4 billion in 2026.
• The last three EBITDA figures came in at $6.4 billion (Q2 2026), $4.0 billion (Q1 2026), and $4.5 billion (Q4 2025), per Business Quant data.